$599

Zealand Dasiglucagon Pediatric Study Meets Primary and Secondary Endpoints

Zealand Pharma announced positive topline results from its pediatric dasiglucagon hypoglycemia rescue trial in pediatric patients from 6 to 17 years of age. Below, FENIX provides insights on dasiglucagon in the context of the recent Lilly Baqsimi (nasal glucagon) and Xeris (subcutaneous Gvoke) FDA approvals.

This content is for Read Less members only.
Register
Already a member? Log in here